Natera's Signatera Gains Japan Approval for Colorectal Cancer
Event summary
- Natera's Signatera received regulatory approval from Japan’s PMDA for colorectal cancer (CRC) in the adjuvant setting.
- Signatera is the first PMDA-approved minimal residual disease (MRD) test in Japan.
- Approval was supported by positive evidence from the GALAXY clinical trial involving 2,240 samples.
- Natera expects to commercially launch Signatera for CRC in Japan by the end of 2026.
The big picture
Natera's Signatera approval in Japan marks a significant milestone in the adoption of MRD testing for colorectal cancer. With over 150,000 CRC cases diagnosed annually in Japan, this approval addresses a critical unmet need and aligns with recommendations from major Japanese medical societies. The success of the GALAXY trial underscores the growing acceptance of precision medicine tools in oncology.
What we're watching
- Market Expansion
- How Natera will leverage this approval to expand Signatera’s reach in Japan and other markets.
- Clinical Validation
- Whether the GALAXY trial results will support further regulatory approvals for Signatera in additional cancer types.
- Commercial Execution
- The pace at which Natera can secure final pricing and achieve commercial launch by the end of 2026.
Related topics